A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.

A PROSPECTIVE, MULTICENTER NON-INTERVENTIONAL STUDY TO EVALUATE THE EFFICACY OF ENBREL (REGISTERED) (ETANERCEPT) OVER A PERIOD OF 12 MONTHS IN THE ROUTINE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, OR PLAQUE PSORIASIS WITH PARTICULAR FOCUS ON THE CLINICAL STATUS IMPROVEMENTS STILL OBSERVABLE AFTER 12 WEEKS OF TREATMENT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02486302

Acronym

ADEQUATE

Enrollment

1534

Registered

2015-07-01

Start date

2015-03-24

Completion date

2017-12-11

Last updated

2019-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Axial Spondyloarthritis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis

Brief summary

The purpose of this non-interventional study is to evaluate the efficacy of etanercept during routine clinical use over a maximum of 12 months in patients with rheumatoid arthritis (RA), psoriatic arthritis(PsA), axial spondyloarthritis(axSpA) or plaque psoriasis (PsO). In so doing, particular attention will be paid to the proportion of those patients who only attain the desired treatment goal after 12 weeks of treatment. The primary efficacy end point for the study is the proportion of patients who attain the desired treatment goal after 12 and 24 weeks,

Interventions

DRUGEtanercept

Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed diagnosis of RA, axSpA, PsA or PsO * No prior treatment with etanercept and eligibility for treatment with etanercept according to the summary of product characteristics.

Exclusion criteria

* The contraindications, special warnings, and precautions according to the summary of product characteristics for etanercept shall apply. * The additional documentation of the patient in another post-marketing study with etanercept is not permitted.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 and Maintained Till 52 Weeks	Week 12 up to Week 52	DAS28 calculated as weighted average of SJC and TJC using the 28 joints count, ESR \[mm/h\] and PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 24	Week 24	DAS28 calculated as average of SJC and TJC using the 28 joints count, ESR (mm/h) and PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. A participant was classified as MAD if the participant met at least 5 of 7 following criteria: 1) TJC t\<=1; 2) SJC =\<1; 3) PASI \<= 1 or BSA \<=3; 4) Participant pain on VAS \<= 15 (assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain \[best\] and 100 mm = maximum possible pain \[worst\]; 5) PtGA on VAS \<= 20 (all assessed on a VAS 0-100cm, where 0 = no disease activity and 100=high disease activity); 6) HAQ-DI \<= 0.5(HAQ=3.16-\[0.028\*FFbH); 7) Tender enthesial points \<= 1.
Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 24	Week 24	ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, PtGA (all assessed on a VAS (0-100cm, where 0 = no disease activity and 100=high disease activity), CRP (mg/L). ASDAS ranged as inactive disease: 0 \<= ASDAS \< 1.3; moderate disease activity: 1.3 \<= ASDAS \< 2.1; high disease activity: 2.1 \<= ASDAS \<= 3.5; very high disease activity: 3.5 \< ASDAS.
Number of Participants With Plaque Psoriasis (PsO) Who Achieved 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score or a Physician's Global Assessment (PGA) of Clear or Almost Clear and DLQI Total Score of 0 or 1 at Week 24	Week 24	PASI:combined assessment of lesion severity & area affected into single score as: 0(no disease)-72(maximal disease). Body divided into=head,upper/lower limbs,trunk;each area scored & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%)-6(90-100%) & severity estimated by clinical signs of erythema,induration,desquamation; range 0(none)-4(very marked). Final PASI=sum of severity parameters for each section\area score\weighing factor(head=0.1,upper limbs=0.2,trunk=0.3,lower limbs=0.4). PASI75:\>=75% reduction in PASI from Baseline. PGA psoriasis:average assessment of erythema,induration,desquamation of all psoriatic lesions, scored on 5-point scale: 0(no psoriasis)-4(severe disease). Clear & almost clear indicate score 0 or 1. DLQI:10-item questionnaire, measures impact of skin disease on participant's quality of life. Each question evaluated on 4-point scale as: 0(not at all)-3 (very much). Total DLQI score:0(no effect)-30(extremely large effect).
Number of Participants With Psoriatic Arthritis (PsA) Who Achieved Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 12	Week 12	DAS28 calculated as average of from SJC and TJC using the 28 joints count, ESR (mm/h), PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. A participant was classified as MAD if the participant met at least 5 of 7 following criteria: 1) TJC \<=1; 2) SJC =\<1; 3) PASI \<= 1 or body surface area (BSA) \<=3; 4) Participant pain on VAS \<= 15 (assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain \[best\] and 100 mm = maximum possible pain \[worst\]; 5) PtGA on VAS \<= 20 (all assessed on a VAS 0-100cm, where 0 = no disease activity and 100=high disease activity); 6) Health assessment questionnaire disability index (HAQ-DI) \<= 0.5(HAQ=3.16-\[0.028\* hannover functional questionnaire \[FFbH\]); 7) Tender enthesial points \<= 1.
Number of Participants With Axial Spondyloarthritis (axSpA) Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 12	Week 12	ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, PtGA (all assessed on a VAS (0-100cm, where 0 = no disease activity and 100=high disease activity), CRP (mg/L). ASDAS ranged as inactive disease: 0 \<= ASDAS \< 1.3; moderate disease activity: 1.3 \<= ASDAS \< 2.1; high disease activity: 2.1 \<= ASDAS \<= 3.5; very high disease activity: 3.5 \< ASDAS.
Number of Participants With PsO Who Achieved 75% Improvement From Baseline in Psoriasis Area & Severity Index(PASI75) Score or Physician's Global Assessment(PGA) of Clear or Almost Clear And Dermatology Life Quality Index(DLQI) Total Score of 0 or 1	Week 12	PASI:combined assessment of lesion severity & area affected into single score as: 0(no disease)-72(maximal disease). Body divided into=head,upper/lower limbs,trunk;each area scored & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%)-6(90-100%) & severity estimated by clinical signs of erythema,induration,desquamation; range 0(none)-4(very marked). Final PASI=sum of severity parameters for each section\area score\weighing factor(head=0.1,upper limbs=0.2,trunk=0.3,lower limbs=0.4). PASI75:\>=75% reduction in PASI from Baseline. PGA psoriasis:average assessment of erythema,induration,desquamation of all psoriatic lesions, scored on 5-point scale: 0(no psoriasis)-4(severe disease). Clear & almost clear indicate score 0 or 1. DLQI:10-item questionnaire, measures impact of skin disease on participant's quality of life. Each question evaluated on 4-point scale as: 0(not at all)-3 (very much). Total DLQI score:0(no effect)-30(extremely large effect).
Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24 and Maintained Till 52 Weeks	Week 24 up to Week 52	DAS28 calculated as weighted average of SJC and TJC using the 28 joints count, ESR \[mm/h\] and PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24	Week 24	DAS28 calculated as weighted average of SJC and TJC using the 28 joints count, ESR \[mm/h\] and PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12	Week 12	Disease activity score based on 28-joints count (DAS28) calculated as weighted average of swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, erythrocyte sedimentation rate (ESR) (millimeter per hour \[mm/h\]) and patient's global assessment (PtGA) of disease activity (recorded on a visual analog scale \[VAS\] scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28 \<2.6 = remission, DAS28 less than or equal to (\<=) 3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Secondary

Measure	Time frame	Description
Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia (inability to feel pleasure in normally pleasurable activities) over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 score ranged from 0-6 (0 indicate not at all: depression/anhedonia can be ruled out; 6 indicate nearly every day: worsening of depression/anhedonia).
Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	The PtGA of disease activity was measured on a VAS ranged from 0 mm to 100 mm, where 0 = no disease activity and 100=high disease activity. Participants assessed their fatigue during the last 7 days using a 0 mm - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Participants assessed pain using a 0 mm - 100 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 ranged from 0-6. PGA disease activity was measured on a 0 mm to 100 mm VAS, with 0 mm = no disease activity and 100mm = maximum possible disease activity. Correlation coefficient between each of these parameters was measured using spearman correlation coefficient and reported.
Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	The PtGA of disease activity was measured on a VAS ranged from 0 mm to 100 mm, where 0 = no disease activity and 100=high disease activity. Participants assessed their fatigue during the last 7 days using a 0 mm - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Participants assessed pain using a 0 mm - 100 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 ranged from 0-6. PGA disease activity was measured on a 0 mm to 100 mm VAS, with 0 mm = no disease activity and 100mm = maximum possible disease activity. Correlation coefficient between each of these parameters was measured using spearman correlation coefficient and reported.
Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	The PtGA of disease activity was measured on a VAS ranged from 0 mm to 100 mm, where 0 = no disease activity and 100=high disease activity. Participants assessed their fatigue during the last 7 days using a 0 mm - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Participants assessed pain using a 0 mm - 100 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 ranged from 0-6. PGA disease activity was measured on a 0 mm to 100 mm VAS, with 0 mm = no disease activity and 100mm = maximum possible disease activity. Correlation coefficient between each of these parameters was measured using spearman correlation coefficient and reported.
Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	The PtGA of disease activity was measured on a VAS ranged from 0 mm to 100 mm, where 0 = no disease activity and 100=high disease activity. Participants assessed their fatigue during the last 7 days using a 0 mm - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Participants assessed pain using a 0 mm - 100 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 ranged from 0-6. PGA disease activity was measured on a 0 mm to 100 mm VAS, with 0 mm = no disease activity and 100mm = maximum possible disease activity. Correlation coefficient between each of these parameters was measured using spearman correlation coefficient and reported.
Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	FFbH consists 18 questions to assess daily activities in last 7 days. Each question is answered by the participant as Yes, I can perform the activity without difficulty (score assigned = 2), Yes, but with some difficulties (score assigned = 1) and No or only with help (score assigned = 0). Final FFbH score (FFbH functional capacity) was then computed according to formula: (Sum of all single scores \* 100% \[percent\]) / (2 \* number of answered questions) ranged between 0-100; higher score indicates better daily activities. Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes \[24 hours\*60 minutes\] was recorded).
Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	FFbH consists 18 questions to assess daily activities in last 7 days. Each question is answered by the participant as Yes, I can perform the activity without difficulty (score assigned = 2), Yes, but with some difficulties (score assigned = 1) and No or only with help (score assigned = 0). Final FFbH score (FFbH functional capacity) was then computed according to formula: (Sum of all single scores \* 100% \[percent\]) / (2 \* number of answered questions) ranged between 0-100; higher score indicates better daily activities. Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes \[24 hours\*60 minutes\] was recorded).
Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	FFbH consists 18 questions to assess daily activities in last 7 days. Each question is answered by the participant as Yes, I can perform the activity without difficulty (score assigned = 2), Yes, but with some difficulties (score assigned = 1) and No or only with help (score assigned = 0). Final FFbH score (FFbH functional capacity) was then computed according to formula: (Sum of all single scores \* 100% \[percent\]) / (2 \* number of answered questions) ranged between 0-100; higher score indicates better daily activities. Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes \[24 hours\*60 minutes\] was recorded).
Percentage of Participants Who Discontinued Treatment Due to Lack of Efficacy or Adverse Events	Baseline up to Week 52	Percentage of participants who discontinued etanercept before completing the study, was reported.
Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Baseline up to Week 52	Participants who switched from etanercept to either disease-modifying antirheumatic drugs (DMARDs) or alternative biologic drug were reported.
Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52	Weeks 12, 24, 36, 52	FFbH consisted 18 questions to assess daily activities in last 7 days. Each question was answered by the participant as Yes, I can perform the activity without difficulty (score assigned = 2), Yes, but with some difficulties (score assigned = 1) and No or only with help (score assigned = 0). Final FFbH score (FFbH functional capacity) was then computed according to formula: (Sum of all single scores \* 100% \[percent\]) / (2 \* number of answered questions) ranged between 0-100; higher score indicated better daily activities.
Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity.
Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity, and C-reactive protein (CRP) (mg/dL). SDAI total score= 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	BASDAI is a validated self-assessment tool used to determine disease activity in participant with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0(no symptoms)-10(very severe symptoms).
Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Occiput-to-wall distance was the distance between the occiput (posterior or back portion of the head) and the wall when the participant stood with heels and shoulder against the wall and the back straight.
Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Percentage of BSA affected by psoriasis was estimated using the palm method: one of the participant's palm to proximal interphalangeal and thumb = 1 percent (%) of total BSA. Regions of the body were assigned specific number of palms with percentage \[Head and neck = 10% (10 palms), upper extremities = 20% (20 palms), Trunk (axillae and groin) = 30% (30 palms), lower extremities (buttocks) = 40% (40 palms)\]. The total BSA affected was the summation of individual regions affected.
Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Each of the 10 fingers and 10 toes was evaluated for dactylitis. Score ranged from 0 to 20, where affected numbers of fingers and toes were evaluated.
Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Baseline, Weeks 12, 24, 36, 52	Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% involvement to 6= 90-100% involvement. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\area score\weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.
Median Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response in Participants With Plaque Psoriasis (PsO)	Baseline up to Week 24	PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%) - 6(90-100%) & severity estimated by clinical signs of erythema, induration, desquamation; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.
Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Weeks 12, 24, 36, 52	PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%) - 6(90-100%) & severity estimated by component score of erythema, induration, desquamation; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Weeks 12, 24, 36, 52	PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%) - 6(90-100%) & severity estimated by clinical signs of erythema, induration, desquamation; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\area score\weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	The DLQI was a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): no effect at DLQI \< 2; small effect at 2 \<=DLQI \<= 5; moderate effect at 6 \<=DLQI \<= 10; very large effect at 11\<=DLQI \<= 20; extremely large effect at 21 \<= DLQI \<= 30.
Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Participant's assessment of pruritus measured on a 100 mm VAS ranging from 0 as no Pruritus to 100 as most severe pruritus.
Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	An enthesis is the site where the joint capsules, ligaments or tendons attach to the bone. Enthesitis is the inflammation of the entheses. This inflammation can lead to severe pain and discomfort.
Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)	Baseline up to Weeks 12, 24, 36, 52	—
Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Baseline up to Weeks 12, 24, 36, 52	—
Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set	Baseline up to Weeks 12, 24, 36, 52	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were measured up to Week 12, 24, 36 and 52 of exposure with study drug that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both SAEs and non-SAEs.
Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Baseline up to Weeks 12, 24, 36, 52	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were measured up to Week 12, 24, 36 and 52 of exposure with study drug that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both SAEs and non-SAEs.
Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	DAS28 calculated as average of from SJC and TJC using the 28 joints count, ESR (mm/h), PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. Participants who had DAS28 \<= 2.6 were considered in remission.
Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Participants answered question: How do you assess your current disease activity? Participants responded by using a 0 - 100 mm visual analog scale where 0 mm = no activity and 100 mm = highest possible activity.
Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.
Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	Participants assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst).
Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	PGA of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity; 100 mm= high disease activity.

Other

Measure	Time frame	Description
Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.
Number of Participants With Rheumatoid Arthritis (RA) Achieving 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Weeks 36 and 52	Weeks 36, 52	DAS28 calculated as average of from SJC and TJC using the 28 joints count, ESR (mm/h), PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. Participants who had DAS28 \<= 2.6 were considered in remission.
Number of Participants With Plaque Psoriasis (PsO) Achieving PASI75 Score or a PGA of Clear or Almost Clear And DLQI Total Score of 0 or 1 at Weeks 36 and 52	Weeks 36, 52	PASI:combined assessment of lesion severity & area affected into single score as: 0(no disease)-72(maximal disease). Body divided into=head,upper/lower limbs,trunk;each area scored & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%)-6(90-100%) & severity estimated by clinical signs of erythema,induration,desquamation; range 0(none)-4(very marked). Final PASI=sum of severity parameters for each section\area score\weighing factor(head=0.1,upper limbs=0.2,trunk=0.3,lower limbs=0.4). PASI75:\>=75% reduction in PASI from Baseline. PGA psoriasis:average assessment of erythema,induration,desquamation of all psoriatic lesions, scored on 5-point scale: 0(no psoriasis)-4(severe disease). Clear & almost clear indicate score 0 or 1. DLQI:10-item questionnaire, measures impact of skin disease on participant's quality of life. Each question evaluated on 4-point scale as: 0(not at all)-3 (very much). Total DLQI score:0(no effect)-30(extremely large effect).
Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than < 2.6 or Meet Minimal Disease Activity (MDA) Criteria at Weeks 36 and 52	Weeks 36, 52	DAS28 calculated as average of from SJC and TJC using the 28 joints count, ESR (mm/h), PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. A participant was classified as MAD if the participant met at least 5 of 7 following criteria: 1) TJC \<=1; 2) SJC =\<1; 3) PASI \<= 1 or body surface area (BSA) \<=3; 4) Participant pain on VAS \<= 15 (assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain \[best\] and 100 mm = maximum possible pain \[worst\]; 5) PtGA on VAS \<= 20 (all assessed on a VAS 0-100cm, where 0 = no disease activity and 100=high disease activity); 6) Health assessment questionnaire disability index (HAQ-DI) \<= 0.5(HAQ=3.16-\[0.028\* hannover functional questionnaire \[FFbH\]); 7) Tender enthesial points \<= 1.
Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than < 1.3 at Weeks 36 and 52	Weeks 36, 52	ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, PtGA (all assessed on a VAS (0-100cm, where 0 = no disease activity and 100=high disease activity), CRP (mg/L). ASDAS ranged as inactive disease: 0 \<= ASDAS \< 1.3; moderate disease activity: 1.3 \<= ASDAS \< 2.1; high disease activity: 2.1 \<= ASDAS \<= 3.5; very high disease activity: 3.5 \< ASDAS.
Number of Participants With Positive Human Leukocyte Antigen B27(HLA-B27) at Baseline for Participants With Axial Spondyloarthritis(axSpA)	Baseline	Participants with Axial Spondyloarthritis with Positive Human Leukocyte Antigen (HLA-B27) were reported.
Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	To assess the pharmacodynamics effect of etanercept on serum levels of autoantibodies, Anti-CCP antibodies levels were measured.
Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 units per milliliter (U/mL) is considered positive.
C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52	Weeks 12, 24, 36, 52	The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Countries

Germany

Participant flow

Participants by arm

Arm	Count
Etanercept All participants with RA, axSpA, PsA, or PsO taking etanercept in the routine treatment as per clinical practice and in line with summary of product characteristics clinical, were observed for a period of 12 months.	1,465
Total	1,465

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Discontinued prematurely	410
Overall Study	Documentation not completed	255
Overall Study	Excluded due to legal reasons	8
Overall Study	Not treated	3

Baseline characteristics

Characteristic	Etanercept	—
Age, Continuous	54.9 years STANDARD_DEVIATION 14.5	—
Race and Ethnicity Not Collected	—	— Participants
Sex: Female, Male Female	901 Participants	—
Sex: Female, Male Male	564 Participants	—

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	5 / 1,465
other Total, other adverse events	606 / 1,465
serious Total, serious adverse events	151 / 1,465

Outcome results

Primary

Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 24

ASDAS is a score combining the assessment of back pain, peripheral pain/swelling, duration of morning stiffness, PtGA (all assessed on a VAS (0-100cm, where 0 = no disease activity and 100=high disease activity), CRP (mg/L). ASDAS ranged as inactive disease: 0 \<= ASDAS \< 1.3; moderate disease activity: 1.3 \<= ASDAS \< 2.1; high disease activity: 2.1 \<= ASDAS \<= 3.5; very high disease activity: 3.5 \< ASDAS.

Time frame: Week 24

Population: PP set=all documented participants who were treated, had at least 1 post-baseline value, AE documented and no major protocol deviation. Overall number of participants analyzed signifies participants of PP set with axSpA evaluable for this outcome measure.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 24	28 Participants

Primary

Number of Participants With Axial Spondyloarthritis (axSpA) Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 12

Time frame: Week 12

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Axial Spondyloarthritis (axSpA) Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 12	38 Participants

Primary

Number of Participants With Plaque Psoriasis (PsO) Who Achieved 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score or a Physician's Global Assessment (PGA) of Clear or Almost Clear and DLQI Total Score of 0 or 1 at Week 24

PASI:combined assessment of lesion severity & area affected into single score as: 0(no disease)-72(maximal disease). Body divided into=head,upper/lower limbs,trunk;each area scored & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%)-6(90-100%) & severity estimated by clinical signs of erythema,induration,desquamation; range 0(none)-4(very marked). Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1,upper limbs=0.2,trunk=0.3,lower limbs=0.4). PASI75:\>=75% reduction in PASI from Baseline. PGA psoriasis:average assessment of erythema,induration,desquamation of all psoriatic lesions, scored on 5-point scale: 0(no psoriasis)-4(severe disease). Clear & almost clear indicate score 0 or 1. DLQI:10-item questionnaire, measures impact of skin disease on participant's quality of life. Each question evaluated on 4-point scale as: 0(not at all)-3 (very much). Total DLQI score:0(no effect)-30(extremely large effect).

Time frame: Week 24

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Plaque Psoriasis (PsO) Who Achieved 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score or a Physician's Global Assessment (PGA) of Clear or Almost Clear and DLQI Total Score of 0 or 1 at Week 24	11 Participants

Primary

Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 24

DAS28 calculated as average of SJC and TJC using the 28 joints count, ESR (mm/h) and PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. A participant was classified as MAD if the participant met at least 5 of 7 following criteria: 1) TJC t\<=1; 2) SJC =\<1; 3) PASI \<= 1 or BSA \<=3; 4) Participant pain on VAS \<= 15 (assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain \[best\] and 100 mm = maximum possible pain \[worst\]; 5) PtGA on VAS \<= 20 (all assessed on a VAS 0-100cm, where 0 = no disease activity and 100=high disease activity); 6) HAQ-DI \<= 0.5(HAQ=3.16-\[0.028\*FFbH); 7) Tender enthesial points \<= 1.

Time frame: Week 24

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 24	106 Participants

Primary

Number of Participants With Psoriatic Arthritis (PsA) Who Achieved Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 12

DAS28 calculated as average of from SJC and TJC using the 28 joints count, ESR (mm/h), PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity. A participant was classified as MAD if the participant met at least 5 of 7 following criteria: 1) TJC \<=1; 2) SJC =\<1; 3) PASI \<= 1 or body surface area (BSA) \<=3; 4) Participant pain on VAS \<= 15 (assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain \[best\] and 100 mm = maximum possible pain \[worst\]; 5) PtGA on VAS \<= 20 (all assessed on a VAS 0-100cm, where 0 = no disease activity and 100=high disease activity); 6) Health assessment questionnaire disability index (HAQ-DI) \<= 0.5(HAQ=3.16-\[0.028\* hannover functional questionnaire \[FFbH\]); 7) Tender enthesial points \<= 1.

Time frame: Week 12

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Psoriatic Arthritis (PsA) Who Achieved Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 12	92 Participants

Primary

Number of Participants With PsO Who Achieved 75% Improvement From Baseline in Psoriasis Area & Severity Index(PASI75) Score or Physician's Global Assessment(PGA) of Clear or Almost Clear And Dermatology Life Quality Index(DLQI) Total Score of 0 or 1

Time frame: Week 12

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With PsO Who Achieved 75% Improvement From Baseline in Psoriasis Area & Severity Index(PASI75) Score or Physician's Global Assessment(PGA) of Clear or Almost Clear And Dermatology Life Quality Index(DLQI) Total Score of 0 or 1	5 Participants

Primary

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12

Disease activity score based on 28-joints count (DAS28) calculated as weighted average of swollen joint count (SJC) and tender joint count (TJC) using the 28 joints count, erythrocyte sedimentation rate (ESR) (millimeter per hour \[mm/h\]) and patient's global assessment (PtGA) of disease activity (recorded on a visual analog scale \[VAS\] scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28 \<2.6 = remission, DAS28 less than or equal to (\<=) 3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Time frame: Week 12

Population: Per-protocol (PP) set=all documented participants who were treated, had at least 1 post-baseline value, AE documented and no major protocol deviation. Overall number of participants analyzed signifies participants of PP set with RA evaluable for this outcome measure.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12	194 Participants

Primary

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 and Maintained Till 52 Weeks

DAS28 calculated as weighted average of SJC and TJC using the 28 joints count, ESR \[mm/h\] and PtGA of disease activity (recorded on a VAS scale of 0 mm-100 mm, where 0 = no disease activity and 100=high disease activity). DAS28\<2.6 = remission, DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Time frame: Week 12 up to Week 52

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 and Maintained Till 52 Weeks	58 Participants

Primary

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24

Time frame: Week 24

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24	203 Participants

Primary

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24 and Maintained Till 52 Weeks

Time frame: Week 24 up to Week 52

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24 and Maintained Till 52 Weeks	88 Participants

Secondary

Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52

FFbH consists 18 questions to assess daily activities in last 7 days. Each question is answered by the participant as Yes, I can perform the activity without difficulty (score assigned = 2), Yes, but with some difficulties (score assigned = 1) and No or only with help (score assigned = 0). Final FFbH score (FFbH functional capacity) was then computed according to formula: (Sum of all single scores \* 100% \[percent\]) / (2 \* number of answered questions) ranged between 0-100; higher score indicates better daily activities. Duration of morning stiffness was defined as the time elapsed when participant woke up in the morning and was able to resume normal activities without stiffness in minutes (If none was present = 0; If morning stiffness was continuing at the time of assessment or was unusual compared to the recent past, average of duration of stiffness over the past 3 days was reported; If stiffness persisted the entire day, 1440 minutes \[24 hours\*60 minutes\] was recorded).

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 12: FFbH vs. Morning stiffness	-0.523 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 24: FFbH vs. Morning stiffness	-0.523 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 36: FFbH vs. Morning stiffness	-0.565 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 52: FFbH vs. Morning stiffness	-0.600 spearman correlation coefficient

Secondary

Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

The PtGA of disease activity was measured on a VAS ranged from 0 mm to 100 mm, where 0 = no disease activity and 100=high disease activity. Participants assessed their fatigue during the last 7 days using a 0 mm - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue. Participants assessed pain using a 0 mm - 100 mm VAS where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst). The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 ranged from 0-6. PGA disease activity was measured on a 0 mm to 100 mm VAS, with 0 mm = no disease activity and 100mm = maximum possible disease activity. Correlation coefficient between each of these parameters was measured using spearman correlation coefficient and reported.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12:PtGA vs. Fatigue	0.582 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. Pain	0.899 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PHQ-2	0.526 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PGA	0.606 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. Pain	0.547 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PHQ-2	0.487 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PGA	0.369 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PHQ-2	0.530 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PGA	0.617 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PHQ-2 vs. PGA	0.392 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Fatigue	0.668 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Pain	0.904 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PHQ-2	0.495 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PGA	0.495 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. Pain	0.664 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PHQ-2	0.634 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PGA	0.445 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PHQ-2	0.492 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PGA	0.515 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PHQ-2 vs. PGA	0.449 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Fatigue	0.720 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Pain	0.914 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PHQ-2	0.630 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PGA	0.586 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. Pain	0.728 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PHQ-2	0.691 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PGA	0.530 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PHQ-2	0.637 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PGA	0.591 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PHQ-2 vs. PGA	0.483 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Fatigue	0.717 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Pain	0.912 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PHQ-2	0.586 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PGA	0.548 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. Pain	0.743 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PHQ-2	0.676 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PGA	0.457 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PHQ-2	0.629 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PGA	0.603 spearman correlation coefficient
Etanercept	Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PHQ-2 vs. PGA	0.420 spearman correlation coefficient

Secondary

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52

BASDAI is a validated self-assessment tool used to determine disease activity in participant with ankylosing spondylitis. Utilizing a VAS of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0(no symptoms)-10(very severe symptoms).

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 12	3.8 units on a scale	Standard Deviation 2.3
Etanercept	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 24	3.5 units on a scale	Standard Deviation 2.3
Etanercept	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 36	3.2 units on a scale	Standard Deviation 2.1
Etanercept	Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 52	3.3 units on a scale	Standard Deviation 2.2

Secondary

Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52

Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% involvement to 6= 90-100% involvement. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.

Time frame: Baseline, Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Baseline	16.8 units on a scale	Standard Deviation 10.1
Etanercept	Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Change at Week 12	-9.6 units on a scale	Standard Deviation 10.3
Etanercept	Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Change at Week 24	-13.0 units on a scale	Standard Deviation 10.6
Etanercept	Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Change at Week 36	-14.4 units on a scale	Standard Deviation 10.9
Etanercept	Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Change at Week 52	-14.8 units on a scale	Standard Deviation 11

Secondary

Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52

The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity. CDAI total score = 0-76. CDAI \<= 2.8 indicates disease remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high disease activity.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 12	12.7 units on a scale	Standard Deviation 9.7
Etanercept	Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 24	11.0 units on a scale	Standard Deviation 9.4
Etanercept	Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 36	10.1 units on a scale	Standard Deviation 8.9
Etanercept	Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 52	9.2 units on a scale	Standard Deviation 9.1

Secondary

Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52

The DLQI was a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): no effect at DLQI \< 2; small effect at 2 \<=DLQI \<= 5; moderate effect at 6 \<=DLQI \<= 10; very large effect at 11\<=DLQI \<= 20; extremely large effect at 21 \<= DLQI \<= 30.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 12	8.3 units on a scale	Standard Deviation 7.4
Etanercept	Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 24	5.5 units on a scale	Standard Deviation 5.8
Etanercept	Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 36	4.8 units on a scale	Standard Deviation 5.5
Etanercept	Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 52	3.7 units on a scale	Standard Deviation 4.6

Secondary

Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52

FFbH consisted 18 questions to assess daily activities in last 7 days. Each question was answered by the participant as Yes, I can perform the activity without difficulty (score assigned = 2), Yes, but with some difficulties (score assigned = 1) and No or only with help (score assigned = 0). Final FFbH score (FFbH functional capacity) was then computed according to formula: (Sum of all single scores \* 100% \[percent\]) / (2 \* number of answered questions) ranged between 0-100; higher score indicated better daily activities.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52	Week 12	71.4 units on a scale	Standard Deviation 22.2
Etanercept	Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52	Week 24	72.2 units on a scale	Standard Deviation 22.4
Etanercept	Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52	Week 36	73.4 units on a scale	Standard Deviation 22.3
Etanercept	Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52	Week 52	73.7 units on a scale	Standard Deviation 22.5

Secondary

Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52

Each of the 10 fingers and 10 toes was evaluated for dactylitis. Score ranged from 0 to 20, where affected numbers of fingers and toes were evaluated.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 12	1.4 finger or toes	Standard Deviation 2.1
Etanercept	Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 24	0.7 finger or toes	Standard Deviation 1.3
Etanercept	Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 36	0.7 finger or toes	Standard Deviation 1.4
Etanercept	Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 52	0.6 finger or toes	Standard Deviation 1.3

Secondary

Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52

Percentage of BSA affected by psoriasis was estimated using the palm method: one of the participant's palm to proximal interphalangeal and thumb = 1 percent (%) of total BSA. Regions of the body were assigned specific number of palms with percentage \[Head and neck = 10% (10 palms), upper extremities = 20% (20 palms), Trunk (axillae and groin) = 30% (30 palms), lower extremities (buttocks) = 40% (40 palms)\]. The total BSA affected was the summation of individual regions affected.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 12	8.5 percentage of BSA	Standard Deviation 12.8
Etanercept	Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 24	5.9 percentage of BSA	Standard Deviation 9.2
Etanercept	Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 36	4.8 percentage of BSA	Standard Deviation 7.1
Etanercept	Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52	Week 52	5.4 percentage of BSA	Standard Deviation 10.9

Secondary

Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52

Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.

Time frame: Weeks 12, 24, 36, 52

Population: PP set=all documented participants who were treated, had at least 1 post-baseline value, AE documented and no major protocol deviation. Number analyzed signifies participants analyzed for this outcome measure at specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52	Week 12	40.9 mm	Standard Deviation 30.1
Etanercept	Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52	Week 24	37.7 mm	Standard Deviation 29.5
Etanercept	Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52	Week 36	36.1 mm	Standard Deviation 28.9
Etanercept	Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52	Week 52	33.5 mm	Standard Deviation 27.8

Secondary

Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52

Participants assessed pain using a 0 mm - 100 mm VAS scale where 0 mm = minimum possible pain (best) and 100 mm = maximum possible pain (worst).

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52	Week 12	38.3 mm	Standard Deviation 26.9
Etanercept	Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52	Week 24	34.9 mm	Standard Deviation 26.3
Etanercept	Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52	Week 36	32.9 mm	Standard Deviation 25.6
Etanercept	Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52	Week 52	31.1 mm	Standard Deviation 24.7

Secondary

Median Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response in Participants With Plaque Psoriasis (PsO)

PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%) - 6(90-100%) & severity estimated by clinical signs of erythema, induration, desquamation; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI75: at least a 75 % reduction in PASI relative to Baseline.

Time frame: Baseline up to Week 24

Arm	Measure	Value (MEDIAN)	Dispersion
Etanercept	Median Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response in Participants With Plaque Psoriasis (PsO)	100 days	Standard Deviation 85.6

Secondary

Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52

An enthesis is the site where the joint capsules, ligaments or tendons attach to the bone. Enthesitis is the inflammation of the entheses. This inflammation can lead to severe pain and discomfort.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52	Week 12	1.0 enthesis	Standard Deviation 1.8
Etanercept	Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52	Week 24	0.6 enthesis	Standard Deviation 1.2
Etanercept	Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52	Week 36	0.4 enthesis	Standard Deviation 1.1
Etanercept	Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52	Week 52	0.3 enthesis	Standard Deviation 1

Secondary

Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52	Week 12	278 Participants
Etanercept	Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52	Week 24	305 Participants
Etanercept	Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52	Week 36	263 Participants
Etanercept	Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52	Week 52	271 Participants

Secondary

Number of Participants Who Switched to Other Therapy After Treatment Discontinuation

Participants who switched from etanercept to either disease-modifying antirheumatic drugs (DMARDs) or alternative biologic drug were reported.

Time frame: Baseline up to Week 52

Population: Treated set included all documented participants who were treated, had at least 1 post-baseline value and had an AE documented. Overall number of participants analyzed signifies participants from treated set who discontinued treatment with Etanercept.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Abatacept	15 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Adalimumab	53 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Apremilast	7 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Azathioprin	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Azathioprin, Leflunomid, Diclofenac	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Azathioprin, Prednisolon	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Baricitinib	3 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Biological NOS	5 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Certolizumab	26 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Etanercept Biosimilar	10 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Golimumab	6 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Hydroxychloroquin	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Leflunomid	4 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Methotrexate (MTX)	6 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	MTX, Adalimumab	2 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	MTX, Prednisolon	3 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	MTX, Tocilizumab	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Prednisolon	13 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Prednisolon, Diclofenac	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Remsima (Infliximab-Biosimilar)	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Rituximab	12 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Roactemra	10 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Secukinumab	27 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Sulfasalazin	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Sulfasalazin, Leflunomid	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Tapentadol	2 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Tocilizumab	25 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Tofacitinib	2 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Ustekinumab	7 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Etoricoxib	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Ibuprofen	2 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Ibuprofen, Metamizol	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Ibuprofen, Prednisolon, Oxycodon, Pregabalin	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Inflectra (Infliximab Biosimilar)	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Infliximab	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	NSAR	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Corticosteroid	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	PUVA	1 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Unknown	5 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	None	56 Participants
Etanercept	Number of Participants Who Switched to Other Therapy After Treatment Discontinuation	Missing values	92 Participants

Secondary

Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were measured up to Week 12, 24, 36 and 52 of exposure with study drug that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both SAEs and non-SAEs.

Time frame: Baseline up to Weeks 12, 24, 36, 52

Population: Treated set included all documented participants who were treated, had at least 1 post-baseline value and had an AE documented.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set	Up to Week 12	417 Participants
Etanercept	Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set	Up to Week 24	567 Participants
Etanercept	Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set	Up to Week 36	651 Participants
Etanercept	Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set	Up to Week 52	699 Participants

Secondary

Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were measured up to Week 12, 24, 36 and 52 of exposure with study drug that were absent before treatment or that worsened relative to pretreatment state. TEAEs included both SAEs and non-SAEs.

Time frame: Baseline up to Weeks 12, 24, 36, 52

Population: PP set=all documented participants who were treated, had at least 1 post-baseline value, AE documented and no major protocol deviation.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 12	416 Participants
Etanercept	Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 24	564 Participants
Etanercept	Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 36	646 Participants
Etanercept	Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 52	694 Participants

Secondary

Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52

Occiput-to-wall distance was the distance between the occiput (posterior or back portion of the head) and the wall when the participant stood with heels and shoulder against the wall and the back straight.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 12	6.7 cm	Standard Deviation 10.7
Etanercept	Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 24	6.6 cm	Standard Deviation 11.3
Etanercept	Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 36	6.3 cm	Standard Deviation 11.2
Etanercept	Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52	Week 52	6.0 cm	Standard Deviation 11

Secondary

Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52

Participant's assessment of pruritus measured on a 100 mm VAS ranging from 0 as no Pruritus to 100 as most severe pruritus.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 12	35.5 units on a scale	Standard Deviation 30.9
Etanercept	Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 24	22.4 units on a scale	Standard Deviation 23.8
Etanercept	Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 36	24.2 units on a scale	Standard Deviation 26.6
Etanercept	Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52	Week 52	14.8 units on a scale	Standard Deviation 15.8

Secondary

Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52

Participants answered question: How do you assess your current disease activity? Participants responded by using a 0 - 100 mm visual analog scale where 0 mm = no activity and 100 mm = highest possible activity.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52	Week 12	39.8 mm	Standard Deviation 24.9
Etanercept	Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52	Week 24	35.5 mm	Standard Deviation 25.1
Etanercept	Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52	Week 36	32.7 mm	Standard Deviation 23.8
Etanercept	Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52	Week 52	30.5 mm	Standard Deviation 23.3

Secondary

Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52

The PHQ-2 is a brief depression screening instrument and enquire two factors: frequency of depressed mood and anhedonia (inability to feel pleasure in normally pleasurable activities) over the past 2 weeks, scoring each question on scale of 0 (not at all) to 3 (nearly every day). Total PHQ-2 score ranged from 0-6 (0 indicate not at all: depression/anhedonia can be ruled out; 6 indicate nearly every day: worsening of depression/anhedonia).

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52	Week 12	2.0 units on a scale	Standard Deviation 1.6
Etanercept	Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52	Week 24	1.8 units on a scale	Standard Deviation 1.6
Etanercept	Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52	Week 36	1.7 units on a scale	Standard Deviation 1.5
Etanercept	Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52	Week 52	1.6 units on a scale	Standard Deviation 1.5

Secondary

Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set

Time frame: Baseline up to Weeks 12, 24, 36, 52

Population: PP set=all documented participants who were treated, had at least 1 post-baseline value, AE documented and no major protocol deviation.

Arm	Measure	Group	Value (NUMBER)
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 12	89.4 percentage of participants
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 24	81.1 percentage of participants
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 36	75.6 percentage of participants
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set	Up to Week 52	71.6 percentage of participants

Secondary

Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)

Time frame: Baseline up to Weeks 12, 24, 36, 52

Population: Treated set included all documented participants who were treated, had at least 1 post-baseline value and had an AE documented.

Arm	Measure	Group	Value (NUMBER)
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)	Up to Week 12	89.5 percentage of participants
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)	Up to Week 24	81.2 percentage of participants
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)	Up to Week 36	75.6 percentage of participants
Etanercept	Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)	Up to Week 52	71.6 percentage of participants

Secondary

Percentage of Participants Who Discontinued Treatment Due to Lack of Efficacy or Adverse Events

Percentage of participants who discontinued etanercept before completing the study, was reported.

Time frame: Baseline up to Week 52

Population: Treated set included all documented participants who were treated, had at least 1 post-baseline value and had an AE documented.

Arm	Measure	Group	Value (NUMBER)
Etanercept	Percentage of Participants Who Discontinued Treatment Due to Lack of Efficacy or Adverse Events	Due to lack of Efficacy	15.2 percentage of participants
Etanercept	Percentage of Participants Who Discontinued Treatment Due to Lack of Efficacy or Adverse Events	Due to Adverse Events	8.5 percentage of participants

Secondary

Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52

PGA of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity; 100 mm= high disease activity.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52	Week 12	32.5 mm	Standard Deviation 21.1
Etanercept	Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52	Week 24	26.9 mm	Standard Deviation 20.5
Etanercept	Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52	Week 36	23.8 mm	Standard Deviation 19.4
Etanercept	Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52	Week 52	21.7 mm	Standard Deviation 18.9

Secondary

Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. Fatigue	0.350 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. Pain	0.606 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PHQ-2	0.563 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PGA	0.606 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. Pain	0.679 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PHQ-2	0.681 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PGA	0.175 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PHQ-2	0.647 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PGA	0.384 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PHQ-2 vs. PGA	0.265 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Fatigue	0.651 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Pain	0.692 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PHQ-2	0.485 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PGA	0.713 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. Pain	0.802 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PHQ-2	0.577 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PGA	0.377 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PHQ-2	0.466 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PGA	0.470 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PHQ-2 vs. PGA	0.219 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Fatigue	0.627 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Pain	0.687 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PHQ-2	0.585 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PGA	0.519 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. Pain	0.744 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PHQ-2	0.812 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PGA	0.288 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PHQ-2	0.659 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PGA	0.411 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PHQ-2 vs. PGA	0.167 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Fatigue	0.418 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Pain	0.625 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PHQ-2	0.464 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PGA	0.753 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. Pain	0.579 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PHQ-2	0.598 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PGA	0.278 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PHQ-2	0.404 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PGA	0.421 spearman correlation coefficient
Etanercept	Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PHQ-2 vs. PGA	0.208 spearman correlation coefficient

Secondary

Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 12, Head	0.4 units on a scale	Standard Deviation 0.8
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 12: Trunk	1.6 units on a scale	Standard Deviation 2
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 12: Upper extremities	1.4 units on a scale	Standard Deviation 1.6
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 12: Lower extremities	3.5 units on a scale	Standard Deviation 3.7
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Head	0.2 units on a scale	Standard Deviation 0.5
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Trunk	0.6 units on a scale	Standard Deviation 0.8
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Upper extremities	0.9 units on a scale	Standard Deviation 1
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Lower extremities	2.3 units on a scale	Standard Deviation 2.7
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Head	0.2 units on a scale	Standard Deviation 0.4
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Trunk	0.5 units on a scale	Standard Deviation 0.9
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Upper extremities	0.5 units on a scale	Standard Deviation 0.5
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Lower extremities	1.5 units on a scale	Standard Deviation 2
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Head	0.1 units on a scale	Standard Deviation 0.3
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Trunk	0.5 units on a scale	Standard Deviation 1
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Upper extremities	0.5 units on a scale	Standard Deviation 0.5
Etanercept	Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Lower extremities	1.4 units on a scale	Standard Deviation 1.9

Secondary

Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)

PASI: combined assessment of lesion severity & area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself & scores combined for final PASI. For each section % area of skin involved was estimated:0(0%) - 6(90-100%) & severity estimated by component score of erythema, induration, desquamation; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 12, Erythema	1.4 units on a scale	Standard Deviation 0.7
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 12: Induration	1.2 units on a scale	Standard Deviation 0.7
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 12: Desquamation	1.1 units on a scale	Standard Deviation 0.7
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Erythema	1.0 units on a scale	Standard Deviation 0.7
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Induration	0.9 units on a scale	Standard Deviation 0.6
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 24: Desquamation	0.9 units on a scale	Standard Deviation 0.7
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Erythema	0.7 units on a scale	Standard Deviation 0.6
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Induration	0.6 units on a scale	Standard Deviation 0.5
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 36: Desquamation	0.6 units on a scale	Standard Deviation 0.5
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Erythema	0.7 units on a scale	Standard Deviation 0.7
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Induration	0.5 units on a scale	Standard Deviation 0.5
Etanercept	Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)	Week 52: Desquamation	0.6 units on a scale	Standard Deviation 0.6

Secondary

Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 12: FFbH vs. Morning stiffness	-0.493 spearman correlation coefficient
Etanercept	Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 24: FFbH vs. Morning stiffness	-0.640 spearman correlation coefficient
Etanercept	Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 36: FFbH vs. Morning stiffness	-0.615 spearman correlation coefficient
Etanercept	Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 52: FFbH vs. Morning stiffness	-0.560 spearman correlation coefficient

Secondary

Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. Fatigue	0.630 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. Pain	0.892 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PHQ-2	0.609 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PGA	0.509 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. Pain	0.664 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PHQ-2	0.601 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PGA	0.324 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PHQ-2	0.628 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PGA	0.529 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PHQ-2 vs. PGA	0.381 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Fatigue	0.656 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Pain	0.881 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PHQ-2	0.562 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PGA	0.559 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. Pain	0.674 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PHQ-2	0.620 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PGA	0.374 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PHQ-2	0.607 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PGA	0.630 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PHQ-2 vs. PGA	0.410 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Fatigue	0.692 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Pain	0.913 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PHQ-2	0.645 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PGA	0.513 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. Pain	0.724 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PHQ-2	0.710 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PGA	0.423 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PHQ-2	0.658 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PGA	0.532 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PHQ-2 vs. PGA	0.357 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Fatigue	0.753 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Pain	0.908 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PHQ-2	0.696 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PGA	0.565 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. Pain	0.760 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PHQ-2	0.726 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PGA	0.430 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PHQ-2	0.683 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PGA	0.581 spearman correlation coefficient
Etanercept	Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PHQ-2 vs. PGA	0.498 spearman correlation coefficient

Secondary

Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 12: FFbH vs. Morning stiffness	-0.439 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 24: FFbH vs. Morning stiffness	-0.486 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 36: FFbH vs. Morning stiffness	-0.520 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52	Week 52: FFbH vs. Morning stiffness	-0.502 spearman correlation coefficient

Secondary

Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (NUMBER)
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA versus (vs.) Fatigue	0.514 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. Pain	0.825 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PHQ-2	0.450 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PtGA vs. PGA	0.603 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. Pain	0.586 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PHQ-2	0.577 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Fatigue vs. PGA	0.370 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PHQ-2	0.529 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: Pain vs. PGA	0.612 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 12: PHQ-2 vs. PGA	0.376 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Fatigue	0.588 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. Pain	0.859 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PHQ-2	0.526 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PtGA vs. PGA	0.600 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. Pain	0.621 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PHQ-2	0.591 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Fatigue vs. PGA	0.389 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PHQ-2	0.558 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: Pain vs. PGA	0.556 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 24: PHQ-2 vs. PGA	0.379 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Fatigue	0.664 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. Pain	0.839 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PHQ-2	0.513 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PtGA vs. PGA	0.609 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. Pain	0.646 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PHQ-2	0.614 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Fatigue vs. PGA	0.463 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PHQ-2	0.532 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: Pain vs. PGA	0.576 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 36: PHQ-2 vs. PGA	0.367 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Fatigue	0.666 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. Pain	0.861 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PHQ-2	0.507 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PtGA vs. PGA	0.632 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. Pain	0.649 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PHQ-2	0.574 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Fatigue vs. PGA	0.485 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PHQ-2	0.545 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: Pain vs. PGA	0.641 spearman correlation coefficient
Etanercept	Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52	Week 52: PHQ-2 vs. PGA	0.445 spearman correlation coefficient

Secondary

Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52

The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity, and C-reactive protein (CRP) (mg/dL). SDAI total score= 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 12	14.3 units on a scale	Standard Deviation 11
Etanercept	Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 24	12.0 units on a scale	Standard Deviation 11.3
Etanercept	Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 36	11.1 units on a scale	Standard Deviation 9.7
Etanercept	Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52	Week 52	10.1 units on a scale	Standard Deviation 10.2

Other Pre-specified

Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52

To assess the pharmacodynamics effect of etanercept on serum levels of autoantibodies, Anti-CCP antibodies levels were measured.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52	Week 12	236.2 unit per milliliter (U/mL)	Standard Deviation 695.7
Etanercept	Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52	Week 24	202.2 unit per milliliter (U/mL)	Standard Deviation 615.6
Etanercept	Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52	Week 36	178.6 unit per milliliter (U/mL)	Standard Deviation 635.3
Etanercept	Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52	Week 52	176.2 unit per milliliter (U/mL)	Standard Deviation 714.4

Other Pre-specified

C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52	Week 12	10.9 mg/L	Standard Deviation 33.9
Etanercept	C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52	Week 24	10.9 mg/L	Standard Deviation 37.4
Etanercept	C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52	Week 36	10.2 mg/L	Standard Deviation 31.4
Etanercept	C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52	Week 52	9.7 mg/L	Standard Deviation 30.3

Other Pre-specified

Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52

ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.

Time frame: Weeks 12, 24, 36, 52

Population: PP set=all documented participants who were treated, had at least 1 post-baseline value, AE documented and no major protocol deviation. 'Number analyzed signifies participants analyzed for this outcome measure at specified time points.

Arm	Measure	Group	Value (MEAN)	Dispersion
Etanercept	Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52	Week 36	18.4 mm/hr	Standard Deviation 17.4
Etanercept	Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52	Week 12	19.7 mm/hr	Standard Deviation 18.4
Etanercept	Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52	Week 24	19.4 mm/hr	Standard Deviation 18.8
Etanercept	Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52	Week 52	18.2 mm/hr	Standard Deviation 17.6

Other Pre-specified

Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than < 1.3 at Weeks 36 and 52

Time frame: Weeks 36, 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than < 1.3 at Weeks 36 and 52	Week 36	35 Participants
Etanercept	Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than < 1.3 at Weeks 36 and 52	Week 52	32 Participants

Other Pre-specified

Number of Participants With Plaque Psoriasis (PsO) Achieving PASI75 Score or a PGA of Clear or Almost Clear And DLQI Total Score of 0 or 1 at Weeks 36 and 52

Time frame: Weeks 36, 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Plaque Psoriasis (PsO) Achieving PASI75 Score or a PGA of Clear or Almost Clear And DLQI Total Score of 0 or 1 at Weeks 36 and 52	Week 36	13 Participants
Etanercept	Number of Participants With Plaque Psoriasis (PsO) Achieving PASI75 Score or a PGA of Clear or Almost Clear And DLQI Total Score of 0 or 1 at Weeks 36 and 52	Week 52	14 Participants

Other Pre-specified

Number of Participants With Positive Human Leukocyte Antigen B27(HLA-B27) at Baseline for Participants With Axial Spondyloarthritis(axSpA)

Participants with Axial Spondyloarthritis with Positive Human Leukocyte Antigen (HLA-B27) were reported.

Time frame: Baseline

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Positive Human Leukocyte Antigen B27(HLA-B27) at Baseline for Participants With Axial Spondyloarthritis(axSpA)	223 Participants

Other Pre-specified

Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than < 2.6 or Meet Minimal Disease Activity (MDA) Criteria at Weeks 36 and 52

Time frame: Weeks 36, 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than < 2.6 or Meet Minimal Disease Activity (MDA) Criteria at Weeks 36 and 52	Week 36	93 Participants
Etanercept	Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than < 2.6 or Meet Minimal Disease Activity (MDA) Criteria at Weeks 36 and 52	Week 52	87 Participants

Other Pre-specified

Number of Participants With Rheumatoid Arthritis (RA) Achieving 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Weeks 36 and 52

Time frame: Weeks 36, 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Rheumatoid Arthritis (RA) Achieving 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Weeks 36 and 52	Week 36	173 Participants
Etanercept	Number of Participants With Rheumatoid Arthritis (RA) Achieving 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Weeks 36 and 52	Week 52	187 Participants

Other Pre-specified

Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52

RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 units per milliliter (U/mL) is considered positive.

Time frame: Weeks 12, 24, 36, 52

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Etanercept	Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52	Week 12	310 Participants
Etanercept	Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52	Week 24	259 Participants
Etanercept	Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52	Week 36	208 Participants
Etanercept	Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52	Week 52	173 Participants

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026

A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Other

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 24

Number of Participants With Axial Spondyloarthritis (axSpA) Who Achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than (<) 1.3 at Week 12

Number of Participants With Plaque Psoriasis (PsO) Who Achieved 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score or a Physician's Global Assessment (PGA) of Clear or Almost Clear and DLQI Total Score of 0 or 1 at Week 24

Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 24

Number of Participants With Psoriatic Arthritis (PsA) Who Achieved Either 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 or Met Minimal Disease Activity (MDA) Criteria at Week 12

Number of Participants With PsO Who Achieved 75% Improvement From Baseline in Psoriasis Area & Severity Index(PASI75) Score or Physician's Global Assessment(PGA) of Clear or Almost Clear And Dermatology Life Quality Index(DLQI) Total Score of 0 or 1

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 12 and Maintained Till 52 Weeks

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24

Number of Participants With Rheumatoid Arthritis (RA) Who Achieved 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Week 24 and Maintained Till 52 Weeks

Ankylosing Spondylitis(axSpA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52

Ankylosing Spondylitis (axSpA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52

Change From Baseline in Psoriasis Area and Severity Index (PASI) in Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52

Clinical Disease Activity Index (CDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52

Dermatology Life Quality Index (DLQI) Total Score for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52

Hannover Functional Questionnaire (FFbH) Functional Capacity Score of Participants With Rheumatoid Arthritis (RA), Axial Spondyloarthritis (axSpA), Psoriasis Arthritis (PsA) at Weeks 12, 24, 36, 52

Mean of Total Number of Affected Fingers or Toes by Dactylitis in Participants With Psoriatic Arthritis (PsA) at Weeks 12, 24, 36 and 52

Mean Percentage of Total Body Surface Area (BSA) for Participants With Plaque Psoriasis (PsO) and Psoriasis Arthritis (PsA) at Weeks 12, 24, 36 and 52

Mean Visual Analogue Scale (VAS) Fatigue Scores at Weeks 12, 24, 36 and 52

Mean Visual Analogue Scale (VAS) Pain Scores at Weeks 12, 24, 36 and 52

Median Time to Achieve Psoriasis Area and Severity Index 75 (PASI 75) Response in Participants With Plaque Psoriasis (PsO)

Number of Affected Enthesis in Participants With Axial Spondyloarthritis (axSpA) and Psoriatic Arthritis(PsA) at Weeks 12, 24, 36 and 52

Number of Participants Achieving 28 Joint Disease Activity Score (DAS28) Remission at Weeks 12, 24, 36 and 52

Number of Participants Who Switched to Other Therapy After Treatment Discontinuation

Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to Weeks 12, 24, 36 and 52: Treated Set

Number of Participants With Treatment Emergent Adverse Events up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set

Occiput-to-wall Distance of Participants With Axial Spondyloarthritis (axSpA) at Weeks 12, 24, 36 and 52

Patient Assessment of Pruritus for Participants With Plaque Psoriasis (PsO) at Weeks 12, 24, 36 and 52

Patient Global Assessment of Disease Activity (PtGA) Scores at Weeks 12, 24, 36 and 52

Patient Health Quessionare-2 (PHQ-2) Scores at Weeks 12, 24, 36 and 52

Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Per-Protocol (PP) Set

Percentage of Participants Who Continued With Treatment up to Weeks 12, 24, 36 and 52: Treated Set (TS)

Percentage of Participants Who Discontinued Treatment Due to Lack of Efficacy or Adverse Events

Physician Global Assessment (PGA) of Disease Activity Scores at Weeks 12, 24, 36 and 52

Plaque Psoriasis (PsO): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Psoriasis Area and Severity Index (PASI) Body Segment Scores in Participants With Plaque Psoriasis (PsO)

Psoriasis Area and Severity Index (PASI) Component Scores in Participants With Plaque Psoriasis (PsO)

Psoriatic Arthritis(PsA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52

Psoriatic Arthritis (PsA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Hannover Functional Questionnaire (FFbH) and Morning Stiffness at Weeks 12, 24, 36, 52

Rheumatoid Arthritis(RA): Spearman Correlation Coefficient Between Patient Global Assessment (PtGA) of Disease Activity, VAS Fatigue, VAS Pain Score, Patient Health Quessionare-2 (PHQ-2) and PGA of Disease Activity at Weeks 12, 24, 36, 52

Simplified Disease Activity Index (SDAI) Scores of Participants With Rheumatoid Arthritis (RA) at Weeks 12, 24, 36 and 52

Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibodies at Weeks 12, 24, 36 and 52

C-Reactive Protein (CRP) Levels at Weeks 12, 24, 36 and 52

Erythrocyte Sedimentation Rate (ESR) at Weeks 12, 24, 36 and 52

Number of Participants With Axial Spondyloarthritis (axSpA) Achieving Ankylosing Spondylitis Disease Activity Score (ASDAS) Less Than < 1.3 at Weeks 36 and 52

Number of Participants With Plaque Psoriasis (PsO) Achieving PASI75 Score or a PGA of Clear or Almost Clear And DLQI Total Score of 0 or 1 at Weeks 36 and 52

Number of Participants With Positive Human Leukocyte Antigen B27(HLA-B27) at Baseline for Participants With Axial Spondyloarthritis(axSpA)

Number of Participants With Psoriatic Arthritis (PsA) Achieving Either 28 Joint Disease Activity Score (DAS28) Less Than < 2.6 or Meet Minimal Disease Activity (MDA) Criteria at Weeks 36 and 52

Number of Participants With Rheumatoid Arthritis (RA) Achieving 28 Joint Disease Activity Score (DAS28) Less Than (<) 2.6 at Weeks 36 and 52

Number of Participants With Rheumatoid Factor (RF) at Weeks 12, 24, 36 and 52